Members of a key reimbursement policy panel on December 6 continued to push for the creation of separate generic price bands for both middle and lower bands under the current three price-band grouping rule as a way to address unreasonable…
HOME > ORGANIZATION
ORGANIZATION
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
- Generic Association to Present Policy Proposal for Govt’s 2020 Honebuto Policy
November 20, 2019
- RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Obituary: Harrison Cook, Eli Lilly
October 15, 2019
- Japan Pharmacist Group Taps Ex-Bureaucrat Isobe for Director Post
October 11, 2019
- Patients Want Access to Innovative Drugs Even If Expensive: PhRMA Survey
October 7, 2019
- PhRMA Chair Urges Japan to Rectify PMP Criteria, Narrow Definition of Innovation
October 4, 2019
- Japan Doctors’ Group to Issue Statement to Push for HPV Vaccines by FY2019-End
October 3, 2019
- Generic Industry Pondering Specific Proposal to Address Unreasonable Price Rises
October 2, 2019
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
- EFPIA Japan Stresses Safety First and Need for Doctors’ Support on Delisting of OTC-Like Drugs, Notes Good Examples Overseas
September 25, 2019
- FPMAJ Sets Up New Taskforce to Promote Access to Japanese Drugs in Asia
September 24, 2019
- Nearly 80% of Japanese Support Insurance Coverage for High-Priced Drugs: Nonprofit Survey
September 18, 2019
- Strengthening Regulatory Science Will Accelerate Innovation in Drug Discovery: JPMA President
September 10, 2019
- Bristol-Myers CEO Caforio Named New PhRMA Chair, Tokyo Visit in October
September 6, 2019
- Number of Sales Reps in Japan Falls Below 60,000 in FY2018, Records 5 Consecutive Years of Decline
August 30, 2019
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…